April 29, 2017
Comments Off on Can CT and MR Shape and Textural Features Differentiate Benign Versus Malignant Pleural Lesions?
SUMMARY: Recent studies have shown that prophylactic radiotherapy should not be routinely used to prevent PTMs in mesothelioma. Instead patients should undergo careful clinical follow-up to ensure PTMs are identified and treated promptly to minimize symptoms.
April 28, 2017
Comments Off on Prophylactic radiotherapy for procedure tract metastases in mesothelioma: a review
CONCLUSION: The method used is appropriate for analyzing problems over complicated domains, such as when the domain changes (as in a solid-state reaction with a moving boundary), when the desired precision varies over the entire domain, or when the solution lacks smoothness. Implementing this method in real-time for clinical applications and in situ monitoring of the under- or over- exposed regions to light during PDT can significantly improve the treatment for mesothelioma.
April 27, 2017
Comments Off on Three-dimensional finite-element based deformable image registration for evaluation of pleural cavity irradiation during photodynamic therapy
CONCLUSIONS: Whether the P/D is extended or not, it shows similarly good outcomes in terms of early results and survival rate. In contrast, a partial pleurectomy, which leaves gross tumour behind, has no impact on survival.
April 26, 2017
Comments Off on Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study
CONCLUSION: Our results indicate that the balance between folic acid uptake, activation and metabolism plays a crucial role in response to pemetrexed-based chemotherapy and the prognosis of MPM patients. Implementing this marker profile in MPM stratification may help to individualize MPM-therapy more efficiently.
April 25, 2017
Comments Off on Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
While recent studies continue to improve our understanding of the types of EE to asbestos still present, challenges remain. We highlighted a few new research directions, such as a need for reliable matrixes to identify common and less recognized environmental exposure types, asbestos biomarker studies specifically focusing on environmental exposures, and research focused on populations and geographic areas that have not been previously studied.
April 24, 2017
Comments Off on Epidemiology of Environmental Exposure and Malignant Mesothelioma.
This review will summarize the biology and diagnostic implication of CD44 and HA as well as the interaction of both molecules in MPM that will demonstrate their potential as biomarkers. Augmentation of the current markers in MPM may lead to an earlier diagnosis and management of this disease.
April 23, 2017
Comments Off on CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
A significant difference in survival was observed in patients undergoing surgery versus no surgery (p = . 008), between the different histological types (p .
April 22, 2017
Comments Off on Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.
The present study also suggested that the Fibulin-3 overexpression may reflect a defensive response of the tissues after exogenous stimuli and may be implicated in cancer development, especially in the context of fluoro-edenite contamination. However, further studies are necessary in order to make Fibulin-3 a customized screening tool.
April 21, 2017
Comments Off on Analysis of fibulin-3 after exposure to asbestos-like fibers.
CONCLUSION: These observations suggest that BAP1Δ does regulate DNA damage response and influences drug sensitivity. It might therefore be relevant to investigate whether patients with high expression of BAP1Δ may be responsive to PARP/PI3K-mTOR.
April 20, 2017
Comments Off on A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.